Baidu
map

Science:埃博拉病毒变异没有人们想象的那么快

2015-03-30 佚名 生物谷

近日,一项研究显示埃博拉病毒变异速度不是人们想象的那么快,这对预防和治疗该疾病来说这是一个好消息。 发表在《科学》杂志上的一篇相关文献显示,由于之前研究资料有限性的原因,之前的研究数据比现在研究的埃博拉病毒变异速度要高出两倍。 但在马里科学家10月和11月间测序的四个埃博拉病毒样本与2014年3月开始流行的病毒样本相比没有发现显著的基因变化。 “持续的西非埃博拉病毒疫情似乎比较稳定,也就

近日,一项研究显示埃博拉病毒变异速度不是人们想象的那么快,这对预防和治疗该疾病来说这是一个好消息。

发表在《科学》杂志上的一篇相关文献显示,由于之前研究资料有限性的原因,之前的研究数据比现在研究的埃博拉病毒变异速度要高出两倍。

但在马里科学家10月和11月间测序的四个埃博拉病毒样本与2014年3月开始流行的病毒样本相比没有发现显著的基因变化。

“持续的西非埃博拉病毒疫情似乎比较稳定,也就是说它的变异速度没有先前的埃博拉病毒疫情爆发时快。”Anthony Fauci说。

经埃博拉病毒诊断测试,抗体和实验性疫苗是基于特定时刻病毒遗传结构制造出来的。如果有太多的遗传变异发生,疫苗和抗体可能变的无效。科学家们说,突变也可能导致更严重的症状或更容易传播病毒。

8月份,病毒学家研究了塞拉利昂99个病毒患者病毒基因组,发现了大量的基因突变。但本次发表的研究报告称,马里收集的埃博拉病毒样本被发现类似过去其他地方收集的病毒样本。Jim Kent说,“收集的新数据增加了更多制造疫苗的可能”,他设立了一个埃博拉病毒基因组数据库。

但在早些时候塞拉利昂的一项研究中Kristian Andersen警告说,新的疫苗和治疗方法可能导致埃博拉病毒突变,这将引起埃博拉病毒的长期存活。

2014年年初以来,在利比里亚、塞拉利昂和几内亚等西非国家,埃博拉病毒杀死了超过10000人,近25000人受感染。

原始出处:

T. Hoenen, D. Safronetz, A. Groseth et al.Mutation rate and genotype variation of Ebola virus from Mali case sequences.Science 27 March 2015: 1407.DOI: 10.1126/science.aaa5646.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
    2015-04-01 jichang
  6. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1994046, encodeId=60cd1994046a5, content=<a href='/topic/show?id=339841561cb' target=_blank style='color:#2F92EE;'>#埃博拉病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41561, encryptionId=339841561cb, topicName=埃博拉病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Thu Mar 03 19:06:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650332, encodeId=d49b165033250, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Sep 01 06:06:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296439, encodeId=6735129643905, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342319, encodeId=9e191342319e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375017, encodeId=7f3e13e50170f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491042, encodeId=62f51491042fd, content=<a href='/topic/show?id=a63ce0908b3' target=_blank style='color:#2F92EE;'>#病毒变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70908, encryptionId=a63ce0908b3, topicName=病毒变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Apr 01 00:06:00 CST 2015, time=2015-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19084, encodeId=ea0e19084fe, content=大样本调查么, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Mon Mar 30 17:22:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
    2015-03-30 cd90

    大样本调查么

    0

相关资讯

美科学家在转基因牛身上培养埃博拉抗体

美国科学家在牛身上培养埃博拉病毒抗体 据外媒报道,在美国南达科他州的一处农场内,有一群转基因牛,它们目前正被科学家专门用于培养可对抗埃博拉病毒的抗体。研究人员希望这些外观看似普通的牛能产生含有足够抗体的血浆,以用于治疗罹患埃博拉病毒的人类。 研发这群牛只的公司执行长苏利文(Eddie Sullivan)表示:“这些动物可产生非常高程度的人类抗体。”鉴于这些牛属于转基因动物,

埃博拉病毒变异或影响新药疗效

美国研究人员20日说,他们已经发现了埃博拉病毒在过去40年中所发生的遗传变异,这些变异可能会影响正在研制中的埃博拉药物的疗效。 根据这项发表在美国《微生物学》杂志上的研究,目前有前景的埃博拉药物大多以病毒基因序列为靶向,可分为3类:单克隆抗体、小分子干扰核糖核酸(siRNA)和磷酰二胺吗啉代寡核苷酸(PMO)药物,它们均基于1976年和1995年在扎伊尔(即今天的刚果民主共和国)流行的埃

Science:中药防己可能用于埃博拉病毒的治疗

埃博拉病毒引起人体致命出血热的零星爆发,但是目前被批准的治疗仍然为零。细胞通过吞噬作用占用埃博拉病毒,其次是通过胞内囊泡的转运方式。然而,很少因素能够控制胞内病毒的运动。在这里,我们发现埃博拉病毒进入宿主细胞需要胞内钙离子通道,此通道被称为两孔通道( TPCs)。通过基因敲除破坏TPC作用,或干扰RNA链,或小分子抑制剂使病毒转运停止,并防止感染。经测试的最有效的小分子——汉防已甲素,可抑制埃博拉

3支埃博拉疫苗“整装待发”

几内亚马桑塔省的一名卫生工作人员正在由法国红十字会管理的埃博拉治疗中心工作。 去年夏末,西方研究人员开始为埃博拉疫苗临床测试打基础时,几内亚是他们选择名单上的最后一个国家。因为它比邻国塞拉利昂和利比里亚每周新感染人数更少,而且患者分布在相当于整个英国国土面积的全国各地,此外这个国家的医疗基础设施十分薄弱。去年10月23日在瑞士日内瓦召开的一次会议上,美国国立卫生研究院(NIH)为利比

埃博拉病毒传入中国的风险有多大?

最近,中国疾病预防控制中心开展的一项研究基于国际航空客运数据分析了西非埃博拉疫区国家的来华旅客人数和目的地,这有助于定量估计2014年第4季度埃博拉病毒病传入中国的风险,为我国疫情的防控与应对准备提供科学依据。 2014年8月8日,世界卫生组织(WHO)宣布西非埃博拉出血热疫情为“国际公共卫生紧急事件”。截至2014年11月21日,全球8个国家(利比里亚、塞拉利昂、几内亚、尼日利亚、塞内加尔、西

J CELL PHYSIOL:美研究发现多种感染疾病通用治疗靶点

根据美国弗吉尼亚州立联邦大学(VCU)本月在Journal of Cellular Physiology发表的一项临床前研究表明,一个称为GRP78的蛋白质,可能是用于治疗人类疾病的一个通用靶标,包括脑癌,埃博拉病毒、流感病毒、肝炎病毒和超级细菌(例如MRSE和MRSA)感染。 通过将临床测试的OSU-03012 (AR-12)和FDA批准的磷酸二酯酶5抑

Baidu
map
Baidu
map
Baidu
map